Biome Australia Reports Record Annual Sales and Consumer Sell-Through
Key points
- Record annual sales revenue of $23.9m in FY26, up 30% from FY25
- Consumer sell-through of Activated Probiotics surpassed 100,000 units in June 2026
- Biome Daily is now the number one probiotic product in Australian pharmacy
- Signed a binding manufacturing agreement with Specialty Probiotics Australia
Full summary
Biome Australia Limited (ASX: BIO) reported a record year in FY26, achieving annual sales revenue of $23.9 million, a 30% increase from FY25. The company also marked a milestone with consumer sell-through of Activated Probiotics surpassing 100,000 units in June 2026. Biome Daily, the company's flagship product, is now the number one probiotic in Australian pharmacies, both in units and dollar value. Additionally, Biome signed a binding manufacturing agreement with Specialty Probiotics Australia to bring the Activated Probiotics range onshore starting September 2026, with no capital investment required.
Outlook
Biome expects 1H FY27 to be its highest revenue-generating half-year on record, supported by new product launches and continued growth in international markets.
Summary generated by a large language model. Please interpret with care.